- Home
- IVVD vs ANL Comparison
IVVD vs ANL Comparison
Compare IVVD & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVVD
- ANL
- Stock Information
- Founded
- IVVD 2020
- ANL 2004
- Country
- IVVD United States
- ANL Cayman Islands
- Employees
- IVVD N/A
- ANL N/A
- Industry
- IVVD Biotechnology: Pharmaceutical Preparations
- ANL
- Sector
- IVVD Health Care
- ANL
- Exchange
- IVVD Nasdaq
- ANL Nasdaq
- Market Cap
- IVVD 63.4M
- ANL 61.8M
- IPO Year
- IVVD 2021
- ANL 2023
- Fundamental
- Price
- IVVD $1.43
- ANL $1.79
- Analyst Decision
- IVVD Strong Buy
- ANL Hold
- Analyst Count
- IVVD 4
- ANL 1
- Target Price
- IVVD $3.64
- ANL N/A
- AVG Volume (30 Days)
- IVVD 15.0M
- ANL 11.6K
- Earning Date
- IVVD 11-13-2025
- ANL 09-26-2025
- Dividend Yield
- IVVD N/A
- ANL N/A
- EPS Growth
- IVVD N/A
- ANL N/A
- EPS
- IVVD N/A
- ANL N/A
- Revenue
- IVVD $46,210,000.00
- ANL N/A
- Revenue This Year
- IVVD $385.94
- ANL N/A
- Revenue Next Year
- IVVD $62.62
- ANL N/A
- P/E Ratio
- IVVD N/A
- ANL N/A
- Revenue Growth
- IVVD 1941.08
- ANL N/A
- 52 Week Low
- IVVD $0.35
- ANL $1.10
- 52 Week High
- IVVD $2.74
- ANL $3.89
- Technical
- Relative Strength Index (RSI)
- IVVD 72.86
- ANL 60.76
- Support Level
- IVVD $0.96
- ANL $1.65
- Resistance Level
- IVVD $1.45
- ANL $1.91
- Average True Range (ATR)
- IVVD 0.19
- ANL 0.10
- MACD
- IVVD 0.05
- ANL 0.00
- Stochastic Oscillator
- IVVD 97.86
- ANL 58.02
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.